Pre-Clinical Malaria Vaccine References

References are listed chronologically

**P27A**


**pfAMA1 DiCo**


**PAM VAR2CSA**


**Var2-CSA DBL2/3-X**


**NMRC-M3V-Ad-Pf5**

No citation.

**CSVAC**

No citation.

**Pf CelTOS FMP012**

Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, et al. Immunization with pre-erythrocytic antigen CelTOS from

**Ad35.CS.01/Ad26.CS.01 (Heterologous adenovirus prime-boost strategy)**
No citation.

**Two-component paediatric malaria vaccine (CS, LSA-1, STARP)**
No citation.

**Pf GAP p52-/p32- (Genetically Attenuated Sporozoites)**

**MSP1 full length**
No citation.

**Pfs25-rEPA/Alhydrogel**


**Pfs25-Pfs25 conjugate vaccine**

**SR11.1**
No citation.

**Pfs48/45**
NMRC-M3V-Ad-PfCA in Adjuvant (7DW8-5)

Clinical Malaria Vaccine References

References are listed chronologically

**RTS,S/AS01E**


**AdCh63/MVA ME-TRAP**


**Adenovirus (Ad35) vectored CS**


**PfSPZ: metabolically active, non-replicating malaria sporozoite vaccine**


**AdCh63/MVA MSP1**


Douglas AD, de Cassan SC, Dicks MD, Gilbert SC, Hill AV, Draper SJ. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using


EBA175 RII


FMP2.1/AS02A (AMA-1 3D7 E. coli-expressed in AS02A adjuvant)


Lyke KE, Daou M, Diarra I, Kone A, Kouriba B, Thera MA, et al. Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in...


**FMP2.1/AS01B (AMA-1 3D7 E. coli expressed in AS01B adjuvant)**


**FMP010/AS01B (MSP-1 42 FVO E. coli-expressed in AS01B adjuvant)**


**GMZ2**


**MSP3 [181-276]**


SE36


NMRC-M3V-Ad-PfCA


NMRC-M3V-D/Ad- PfCA Prime/Boost
No citation.

AMA1-C1/Alhydrogel®+ CPG 7909


**BSAM-2/Alhydrogel®+CPG 7909**
No citation.

**CSP, AMA1 virosomes (PEV 301,302)**


**VMP001/AS01B**


**AdCh63 AMA1/MVA AMA1**
No citation.

**polyepitope DNA EP1300**
No citation.

**JAIVAC (MSP1 19/EBA175)**
No citation.
Inactive or Discontinued Malaria Vaccine References

References are listed chronologically

**RTS,S/AS02A**

See RTS,S/AS01E on Clinical Sheet

**GLURP [85-213]**


**AMA1-FVO [25-545]**


**FP9/MVA Polyprotein**


**FMP011/AS01B (LSA-1   E. coli-expressed in AS01B adjuvant)**

**FMP011/AS02A (LSA-1   E. coli-expressed in AS02A adjuvant)**


Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, et al. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine 2010 Jul 12;28(31):5135-5144.

**FMP1/AS02A (MSP-1 42 3D7 E. coli-expressed in AS02A adjuvant)**


**MSP1-C1/AIOH/AIOH + CpG**


**MSP2-C1/ISA720**

Abstract information only

[http://www.astmh.org/AM/Template.cfm?Section=Meeting_Archives&Template=/CM/ContentDisplay.cfm&ContentID=2316](http://www.astmh.org/AM/Template.cfm?Section=Meeting_Archives&Template=/CM/ContentDisplay.cfm&ContentID=2316)

Abstract number 1076

**AMA1-C1/ ISA720**


**PfCP2.9 (MSP-1 19/AMA-1 chimera)**


**DNA/MVA CS**


**FP9/MVA & DNA/MVA ME-TRAP**


**HepB Core-Ag CSP VLP**


**RTS,S/AS02 + MVA CSP**

RTS,S/AS02 / DNA CSP


CSP long synthetic peptide


CSP DNA Immunization


Epstein JE, Gorak EJ, Charoenvit Y, Wang R, Freydberg N, Osinowo O, et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and

**FP9 CSP + LSA-1 epitope/ MVA-CSP + LSA-1 epitope**


**DNA/MVA prime-boost Multi-Epitope (ME) string + TRAP**


**FP9 MVA prime-boost ME-TRAP**


**RTS,S/AS02 and TRAP**
No citation.

**AMA-1 (Australia)**


**RESA, MSP1, MSP2 (combination B)**


**Pfs25**

**Pvs25**


**FMP-1 (MSP-1 42 3D7) + RTS,S (CSP)**

Ogutu BR. A Double-blind, Randomized, Controlled, Phase IIb Field Trial in 12 to 47 Month-old Children in Western Kenya to Evaluate the Efficacy, Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine (WRAIR’s MSP-1 Antigen Adjuvanted in GlaxoSmithKline Biologicals’ AS02A) Versus Rabies Vaccine.

**NMRC-MV-Ad-PfC**
Abstract Only

http://www.astmh.org/AM/Template.cfm?Section=Meeting_Archives&Template=/CM/ContentDisplay.cfm&ContentID=1511

Abstract number 304

LSA-3 (inactive)


MuStDO5 (Multi-Stage DNA vaccine Operation, 5 antigens)


PvRII


Spf66


